Rise of the IMiD Biologic Therapies

 1990s, several thalidomide analogs were synthesized to increase efficacy and minimize toxicity.

 2006 FDA approves Lenalidomide (Revlimid).

 Revlimid is felt to be 50 to 2000 more potent than thalidomide.

 Phase 2 trial 91% new myeloma achieved responses with Lenalidomide plus dexamethasone.

 2013 FDA approves Pomalidomide.

 Pomalyst and dexamethasone given to multi-refractory myeloma with response rates of 35 to 65%.

 Combination of pomalidomide, bortezomib, and dexamethasone in relapsed MM response rates of 72%.

 Iberdomide (CC-220) is the newest in the class and is now in clinical trials

 CELMODs are the next class of IMiD with CC92480 drug more potent than iberdomide